Symptomatic hypocalcemia with oral clodronate

Area of Science:

• Oncology
• Endocrinology
• Gastroenterology

Background:

• Prostate cancer with bony metastases can lead to complex metabolic disturbances.
• Previous bowel resection for Crohn's disease may predispose patients to subtle endocrine dysfunction.
• Bisphosphonates, like clodronate, are used to manage bone metastases but can impact calcium homeostasis.

Observation:

• A patient with prostate cancer and a history of bowel resection developed symptomatic hypocalcemia during oral clodronate therapy.
• The patient also experienced hypomagnesemia and hypokalemia attributed to diarrhea.
• Normocalcemia was maintained prior to clodronate, suggesting an interaction with the medication and prior surgery.

Findings:

• Clodronate's inhibition of osteolysis may have unmasked or exacerbated underlying hypocalcemia.
• Concomitant hypomagnesemia significantly contributed to refractory hypocalcemia and hypokalemia.
• Diarrhea played a role in the electrolyte imbalances, complicating the clinical picture.

Implications:

• Bisphosphonate use requires careful consideration in patients with a history of bowel surgery.
• Magnesium status is critical in the assessment and management of hypocalcemia, particularly in patients with gastrointestinal issues.
• This case highlights the interplay between cancer treatment, prior surgery, and electrolyte balance.